CanariaBio CEO Nahanik Participates as Speaker at East Asia Gynecologic Oncology Research Society Symposium

[Asia Economy Reporter Jang Hyowon] Nahanik, CEO of Canaria Bio, announced on the 25th that he will participate as a speaker at the 25th East Asia Gynecologic Oncology Research Society Symposium held at Seoul Asan Medical Center on Saturday.

At this symposium, two pharmaceutical companies, AstraZeneca and Canaria Bio, will present. CEO Nahanik will introduce the ovarian cancer treatment Oreogobomab and participate in a discussion session.

Ovarian cancer is a cancer with a very high unmet medical need, but next-generation new drugs have not yet been developed.

Oreogobomab, a first-line ovarian cancer treatment developed by Canaria Bio, showed a progression-free survival period (the period during which the disease does not progress) of 42 months when administered in combination with chemotherapy in phase 2 clinical trials. This is an increase of 30 months compared to the control group that received only chemotherapy (12 months).

The East Asia Gynecologic Oncology Research Society, the largest gynecologic cancer academic event in Asia, is attended mostly by member professors from the gynecologic oncology research societies of Korea, China, Japan, and Taiwan.

CEO Nahanik said, “If Oreogobomab is approved, I will clearly convey the superiority of Oreogobomab at this event where all the professors who will prescribe it will gather in one place.”